ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fluorine F 18 fluorothymidine
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
FLT PET/CT in Measuring Response in Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: EAI141, NCI-2015-00328, NCT02392429
18F-FLT PET Imaging in Assessing Tumors and Measuring Response in Younger Patients With Brain Tumors
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 21 and under
Trial IDs: PBTC-N12, NCI-2013-00805, NCT01244737
Onalespib in Treating Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9875, NCI-2015-01681, 15-XXX, 16-712, NCT02572453
Multi-tracer PET in Imaging Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: HCI31335, NCI-2014-01824, 31335, NCT00813566
[F-18] FLT PET in Measuring Tumor Response in Patients with Solid Tumors or Hematopoietic Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 2006-127, NCI-2015-01345, 0905007082, NCI-2015-01231, WSU-2006-127, PFIZER-WSU-2006-127, NCT00935090
FDG-PET/CT or [18F]-FLT-PET/CT in Measuring Treatment Response in Patients with Breast Cancer Receiving Chemotherapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: VICC BRE 09108, NCI-2015-02059, JOHNSO7508272014094127, NCT01222416
Positron Emission Tomography-Computed Tomography in Monitoring Treatment in Patients with Diffuse Large B-Cell Lymphoma Receiving First-Line Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: LYMIMG0001, NCI-2012-02178, NCT01410630
Fluorothymidine-Labeled Positron Emission Tomography in Measuring Response in Patients With Previously Untreated Intermediate- or High-Risk Myelodysplastic Syndrome Receiving Azacitidine
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: HO10417, NCI-2012-00362, 2011-0285, NCT01535456
18F-FLT-PET in Predicting Response in Patients with Metastatic Breast Cancer to the Brain Undergoing Whole Brain Radiation Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 12-039, NCI-2015-01799, NCT01621906
18F-FLT PET/CT in Sparing Bone Marrow in Patients With Gynecologic Cancer Undergoing Radiation Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: UPCC 28813, NCI-2014-00861, 819177, NCT02108457
Serial FLT PET Imaging in Monitoring Response to Treatment in Patients with Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 14-050, NCI-2016-00956, NCT02139150
18F-FLT PET/CT in Measuring Cell Proliferation in Patients with Brain Tumors
Status: Temporarily closed
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 7754, NCI-2013-02162, NCT02167204
FLT PET in Predicting Malignant Tumors in Patients with Neurofibromatosis Type I
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 10 and over
Trial IDs: 14-C-0163, NCI-2014-02502, P141559, NCT02211768
Dexamethasone Effects in Patients with Refractory Advanced Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: Any age
Trial IDs: 2015-174, NCI-2016-00881, NCT02819024
18F-FLT PET/CT and PET/MR in Assessing Response to Dual Checkpoint Inhibitor Therapy in Patients with Metastatic or Stage III Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 201602062, NCI-2016-01317, NCT02891616
Start Over